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Cyanotic nephropathy and use of non-ionic contrast agents
during cardiac catherization in patients with cyanotic congenital
heart disease
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Abstract Background: Chronic cyanosis with its associated rheologic changes is a known risk factor for
glomerular nephropathy. Therefore, contrast-induced nephrotoxicity should be an important consideration
for angiographers comparable to diabetics. On the other hand, progressions in diagnostic and interventional
techniques have led to expanded indications and a more widespread use of x-ray contrast agents. The aim of
this study was to investigate the risk of contrast-induced nephropathy in the small group of patients with
cyanotic heart disease prior to surgical repair. Methods: We investigated 23 cyanotic patients with an oxygen
saturation of 82 (50—92) %, age 25 (5-63) years, and 13 control subjects with atrial septal defect, age 37
(20—66) years. Blood viscosity was measured before and after cardiac catherization. Renal damage was eval-
uatated by selective analysis of urinary proteins and enzymes. Results: Before cardiac catheterization, 48 % of
the cyanotic patients had a moderate glomerulopathy. Cardiac catherization was performed with 3.0 (1.2 —
6.8) mls/kg non ionic contrast medium. Only one of the 23 patients (4.3 %) with normal urinary analysis
before cardiac catheterization showed renal damage, which involved tubular and glomerular function.
Elevated blood viscosity in cyanotic patients was slightly reduced by the contrast. None of the acyanotic
controls had contrast-induced nephropathy. Conclusions: The use of non-ionic contrast medium does not
worsen cyanotic glomerulopathy. This finding may be due to the reduction of blood viscosity by the appli-
cation of the contrast medium. The finding of contrast-induced nephropathy in one patient underlines the
importance of monitoring renal function after cardiac catheterization.
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NEPHROPATHY HAS LONG BEEN RECOGNIZED asa potential complication of chronic cyanoticcongenital heart disease.1 Recent studies
with a selective and discriminating urinary analysis
have revealed glomerular lesions to be the
prominent feature of renal disease, although there
may be a mild accompanying tubular
dysfunction.2^* An increased hematocrit was postu-
lated to be involved in the pathogenesis of the renal
damage in chronic cyanotic patients.2"3
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Contrast-induced nephrotoxicity is a common
concern among angiographers in groups of
patients like diabetics, who are known to be at
increased risk. The causes of contrast-induced
nephrotoxicity are not well understood. The
identification and preparation of patients at risk
are important. 5
On the other hand, progression in diagnostic
and interventional techniques has led to expanded
indications and a more widespread use of x-ray
contrast agents. Because of this, we investigated
the risk of contrast-induced nephropathy in the
small group of patients with cyanotic congenital
heart disease prior to surgical repair.
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Patients and methods
Patient selection
We studied 23 consecutive patients with cyanotic
congenital heart disease older than 5 years of age,
who presented to our hospital for cardiac catheteri-
zation between May 1998 to March 1999. Patients
with congenital renal abnormalities (n=l ) , a
history of endocarditis (n= l ) or diabetes (n=2)
were excluded from the investigation. The control
group comprised 13 acyanotic patients with atrial
septal defect (Table 1). The study protocol was
approved by the Ethics Committee of the
Humboldt University, Berlin. Patients, and parents
of patients younger than 18 years, gave informed
consent to participate in this study.
Evaluation of renal function
Renal function was evaluated by analysis of proteins
and enzymes analysis in spontaneously voided
samples of urine taken before and 24 hours after
cardiac catheterization. Protein- and albuminuria,
as well as the appearance of the high molecular
proteins transferrin and immunoglobuline G in the
urine, gave evidence for glomerular lesions.
Presence of ctj-microglobulinuria, and increased
activity of the N-acteyl-fi-D-glucosaminidase, indi-
cated tubular damage. Serum creatinine and urea
were analyzed by a Hitachi 917®-analyzer with
commercial test kits (Boehringer, Mannheim,
Germany). Urinary total protein, albumin, ctj-
microglobulin, transferrin, immunoglobuline G
and the activity of the N-acteyl-fi-D-
glucosaminidase were analyzed and expressed as
ratios relative to creatinine as previously described.2
Cardiac catheterization
Cardiac catherization was performed after
overnight fasting. If the procedure did not take
place in the early morning, patients recieved 500 or
1000 mis of intravenous isotonic electrolyte
solution prior to the investigation. Angiography
was performed using the monomeric non-ionic
contrast medium iopromide (Ultravist 370®,
Schering, Berlin, Germany).
Probe schedule
A first blood sample, and a specimen of urine, were
taken after the overnight fasting prior to cardiac
catheterization. A second blood sample was taken
at the end of the investigation. A second urine
sample was taken 24 hours after the end of
catheterization.
Evaluation of blood rbeology
Hematocrit, hemoglobin and red cell index were
measured using a Coulter counter model Celldyn
3500® (Abbott, Illinois, USA). Viscosity was
Table 1. Urine analysis in cyanotic heart disease and ASD-controls before cardiac catherization
value
Total protein
(> 150 mg g~'crea counted
as pathological)
Albumin
(> 35 mg g"'crea counted
as pathological)
[alpha], -microglobulin
(> 16 mgg"'crea
counted as pathological)
Transferrin
(> Omgg-'crea
counted as pathological)
Immunglobulin G
(> 0 mgg~'crea
counted as pathological)
N-acteyl-a-D-
glucosaminidase
(> llUg-'crea
counted as pathological)
Cyanotic heart disease
n = 23
No. of patients with
pathological analyzis
range (mg g-'crea)
8
(229-3327)
11
(41-2829)
3
(24.2-267.3)
10
(0.8 - 242)
7
(1.3-171)
2
(15.7-18.3)
ASD controls
n = 13
No. of patients with
pathological analyzis
range (mg gr'crea)
1
(4220)
1
(2232)
1
(18.2)
1
(180)
1
(42)
0
P -
0.0009
0.043
n.s.
0.021
0.034
0.04
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measured using a cone and plate viscosimeter
(Wells-Brookfield, Massachusetts, USA) at shear
rates of 11.3 s"1 and 230 s"1 at a temperature of
37°C. Blood samples were anticoagulated with
dipotassium EDTA, kept at 8 °C, and measured
within 5 hours. Viscosity was measured after equili-
bration with a mineral oil standard (Wells-
Brookfield, Massachusetts, USA) on 0.5 ml
samples of either whole blood, or plasma obtained
after centrifugation for 10 min at 3000g.
Analysis of data
Statistical analysis was performed using the Mann-
Whitney-U-test for unpaired samples and
Spearman correlation coefficients with the statistical
package of social analyses.
Results
The diagnoses of the 23 cyanotic patients are listed
in Table 2. Seven of them had previoulsy undergone
cardiac surgery, either construction of aorto-
pulmonary shunts or corrective surgery leaving
residual defects, which had been performed with
cardiopulmonary bypass in 6 cases.
Before catheterization, the serum creatinine
was 0.83 (0.51-1.31) mg/dl in the cyanotic and
0.91 (0.78—1.45) mg/dl in. the acyanotic groups
(n.s.). Serum urea was 31 (18-48) mg/dl versus 25
(20-35) mg/dl (p = 0.048). In the cyanotic group,
11 of the 23 (48 %) patients had increased albu-
minuria (> 35 mg g^crea), 8 (35 %) of them with
elevated concentration of urinary protein (> 150
mg g~'crea). In 3 patients (13 %) there was
elevation in the concentration of urinary o^-
microglobulin (> 16 mg g~'crea), and 2 (8.7 %)
Table 2. Diagnoses of patients with cyanotic congenital heart
disease
Dianoses Patient numbers
Tetralogy of Fallot or
Double outlet right ventricle with
pulmonary stenosis
Tetralogy of Fallot with pulmonary attesia
Complete transposition with VSD and
pulmonary stenosis
VSD or patent arterial duct with
Eisenmenger syndrome
Double inlet left ventricle with discordant
ventriculo-arterial connection and
pulmonary stenosis
Congenitally corrected transposition with
VSD and pulmonary stenosis
Tricuspid atresia with restrictive VSD
Ebstein's malformation with ASD
VSD — ventricular septal defect; ASD — atrial septal defect
patients had elevated urinary activity for N-
acteyl-(3-D-glucosaminidase (> 11 U g~'crea)
(Table 1). In the cyanotic patients, the hematocrit,
blood and plasma viscosity were all elevated, and
mean corpuscular volume and mean corpuscular
hemoglobin were decreased compared to
acyanotic controls (Table 3). In the cyanotic
patients, blood but not plasma viscosity was
correlated to hemoglobin, hematocrit and oxygen
saturation (Table 4). No correlation was found
between age, oxygen saturation, blood- and
rheology parameters to the parameters for the
urine. In the control group, only one (8 %) patient
had a pathologic albuminuria and elevated
urinary total protein concentration (Table 1). In
all other acyanotic patients, analysis of urine prior
to catherization was normal.
The amount of contrast medium was 3.0 (1.2 —
6.8) mls/kg in the cyanotic and 0.73 (0.5 - 2.7)
mls/kg in the control group (p < 0.01). After
cardiac catheterization, the viscosity of whole
blood viscosity decreased in 14 of the 23 cyanotic
patients from mean 17.2 to 12.9 CPS (p > 0.05)
(Fig. 1). Plasma viscosity increased in 13 from 23
cyanotic patients from mean 3-47 to 6.75 CPS
(p = n.s.) (Fig. 2). Urinary albumin concen-
tration decreased in 2 cyanotic patients with
pathological measurements before cardiac
catheterization (Fig. 3). The patient with the
highest concentration of albumin in the urine was
the one with the highest whole-blood viscosity
(Fig. 1). The concentration of albumin in the
urine increased in 1 cyanotic patient, whose
analyses had been non-pathological prior to
cardiac catherization, to pathologic values after
cardiac catherization (Fig. 3). This increase of
urinary albumin in this particular patient was
associated with an increase in urinary N-acteyl-
(5-D-glucosaminidase to highly pathologic levels
(Fig. 4). In this patient who was aged 13 years
and had the diagnosis of tetralogy of Fallot, with
an oxygen saturation of 81 %, and hematocrit of
63 %, the exposure to contrast was 4.2 mls/kg. In
the other cyanotic patients, urinary N-acteyl-(3-
D-glucosaminidase was slightly elevated in 2
cases, staying at the same level prior to and after
catheterization (Fig. 4). In the control group,
none of the patients developed pathological
features of urinary analyzis (Figs 3, 4).
Discussion
Our data show that the use of non-ionic monomer
contrast agent is rarely detrimental to renal
function in patients with cyanotic congenital heart
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Table 3. Viscosity measurements in cyanotic heart disease and ASD-controls before cardiac catheterization
11
value
Cyanotic heart disease
n=23
median (range)
ASD controls
n=13
median (range)
Oxygen saturation (%)
Whole-blood viscosity
11.3s-1(CPS)
Whole-blood viscosity
225s"1(CPS)
Plasma viscosity
11.3s-l(CPS)
Plasma viscosity
225 s"1 (CPS)
Hematocrit (%)
MCV(fl)
MCH(pg)
MCHC(g/dl)
82
(50-92)
12.9
(6.31-28.2
5.4
(3,37-9,95)
2.87
(2.25-7.95)
1.59
(1.24-2.5)
53.8
(37.8-75.2)
87
(67.7-96.8)
28.8
(20.3-32.7)
33.2
(29.4-35.2)
99
(90-100)
8.42
(6.58-11.4)
4.44
(3,77-5,44)
2.04
(1.84-4.09)
1.49
(1.29-1.63)
43.1
(37.6-51)
91.3
(85.9-98.5)
30.7
(27.8-34)
33.7
(32.3-34.6)
0.0001
0.001
0.004
0.004
n.s.
0.002
0.014
0.007
0.035
CPS — Centipoise; MCV — mean corpuscular volume; MCH — mean corpuscular hemoglobin; MCHC — mean corpuscular hematocrit
Table 4. Correlation between hematocrit and oxygen saturation to blood viscosity in cyanotic patients
Blood viscosity (CPS)
(shear rate 225 s-1)
Hemoglobin (g/dl)
Hematocrit (%)
Oxygen saturation (
r = 0.91, p < 0.01
r = 0.95, p < 0.01
r = -0.67, p < 0.01
Blood viscosity (CPS)
(shear rate 11.3 s—1)
r = 0.76, p < 0.01
r = 0.82, p < 0.01
r =-0.75, p < 0.01
blood viscosity (shear
rate 11.3/s, CPS)
35 -
CyanoUc heart disease
30
25-
20
15
10
ASD controls
pre - post
catheterization
pre
catheterization
post
Figure 1.
Whole-blood viscosity pre and post cardiac catheterization: Blood viscosity at shear rate 11.3 s-1, representing arteriolar flow conditions, was
elevated in cyanotic patients compared to acyanotic controls (p = 0.001). After cardiac catheterization, blood viscosity was slightly reduced in most
patients (p < 0.05).
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plasma viscosity (shear
rate 11.3/s, CPS)
12
10
6
2
Cyanotic heart disease
ASD controls
catheterization
pre - post
catheterization
Figure 2.
Plasma viscosity pre and post cardiac catheterization: Plasma viscosity at shear rate 11.3 r1, representing arteriolarflow conditions, was slightly
elevated in cyanotic patients compared to acyanotic controls (p = 0.004). After cardiac catheterization, plasma viscosity was changed in both
directions in individual patients and did not differ significantly to pre catheterization values.
albuminuria (mg g-1 creatinine)
3000
2500
2000
1500
1000
Cyanotic heart disease
(n-23)
pre - post
cathetenzatlon
Figure 3.
Urinary albumin concentration pre and post cardiac catheterization: Eleven patients in the cyanotic group and 1 patient in the ASD group had a
glomerulopathy with albuminuria > 35 mg g—1 creatinine before catherization (p = 0.04). One cyanotic patient (asterix) with normal pre
catherization analyzis developed albuminuria of 730 mg g—1 creatinine, associated with renal tubular damage (see asterix in Fig 4).
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0-NAG (U g-1 creatinine)
1000
100
10
Cyanotic heart disease
(n-23)
ASD controls
(n-13)
pre - post
catheterization
ore - post
catheterization
Figure 4.
N-acteyl-fi-D-glucosaminidase activity in the urine pre and post cardiac catheterization: Before catherization, only 2 cyanotic patients showed
moderate tubular damage as indicated by slightly elevated N-acteyl-fi-D-glucosaminidase (> 11 U g—1 creatinine), thus underlining the
primary glomerular character of nephropathy in long standing cyanosis. One patient (asterix) showed contrast induced tubular damage with an
increase of the N-acteyl-fi-D-glucosaminidase to 280 U g—1 creatinine.
disease, even in those who exhibited moderate
glomerular damage (Table 1). In all but one
patient, no new glomerular or tubular renal
damage could be found after administration of
contrast (Figs 3, 4). We used non-ionic contrast
agent. The advantages of non-ionic over ionic
monomer contrast agents with regards to chemo-
toxicity and osmotoxicity have been demonstrated
before in a number of studies.6"12 Although the
evidence is inconclusive, radiocontrast-induced
nephropathy has been shown to result from an
ischemic injury to the medullary portion of the
kidney secondary to intense renal vasocon-
striction.13-14 The low risk found in our patients
may be due to a positive effect of the contrast agent
on blood viscosity (Fig. 1) which, in turn, improves
the properties of arteriolar flow in this special group
of patients with erythrocytosis.2'3'15 The medullary
portion of the kidney is provided by a second
capillary bed, which is in series after the glomerular
capillaries. To maintain normal blood flow in the
peritubular capillaries though the increased
resistance to flow of viscous blood in patients with
elevated hematocrit, a higher intravascular
pressure is required, which results in proteinuria
(Table I).16 Previous important impairment of renal
function has been found to be a risk factor for renal
damage by contrast media.5-13-17"19 But, in chronic
cyanotic heart disease, only moderate glomerular
lesions and only a mild accompanying tubular
dysfunction (Table I)2"4 are the prominent features
of renal impairment.2-3 Thus, our results confirm
the reported low risk in the use of non-ionic
contrast agents.20 In turn, the relatively low irri-
tability of cyanotic patients to radiocontrast
induced medullary hypoxia provides further
evidence for the glomerular character of cyanotic
nephropathy.
Moderate tubular damage appearing in one
patient without cyanotic glomerulopathy shows that
there is a small, but definite, risk for radiocontrast-
induced nephropathy even in patients at low risk
who are undergoing elective cardiac catheterization.
This can be detected only when very sensitive labo-
ratory tests are employed.20 Our procedure of intra-
venous fluid substitution if fasting took more than 8
hours may have helped to keep the incidence of
radiocontrast-induced nephropathy low, as careful
hydration and production of a high flow of urine
have been shown the only prooven method to
minimize the incidence of radiocontrast-induced
nephropathy in patients known to be at risk.13-21-22
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Limitations of this study
In this retrospective analyis, the amount of the
contrast agent used in the control patients was lower,
which may have influenced the findings, as changes
in rheology or renal function can be influenced by
the degree of cyanosis or the dose of contrast
agent.23"25 Since we did not find a significant increase
in renal impairment in our patients, and essentially
report a negative effect, the lower dose of contrast is
unlikely to have influenced our data.
Conclusions
From our data, we conclude that it is advisable to
monitor renal function in patients with cyanotic
congenital heart disease who undergo cardiac
catheterization, but note that use of non-ionic
monomer contrast agents does not generally lead
to further impairment of renal function in patients
with cyanotic glomerulopathy. Good hydration
may help to keep low the risk of radiocontrast-
induced nephropathy.
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